Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive allosteric modulator(PAM) in development for the treatment of schizophrenia.
We believe emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development.